Parallax Volatility Advisers
QNCX icon

Parallax Volatility Advisers’s Quince Therapeutics QNCX Stock Holding History

Parallax Volatility Advisers’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-175
Closed -$217K – 3182
2022
Q1 		$217K Buy
+175
New +$238K ﹤0.01% 2157

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Parallax Volatility Advisers's QNCX Position: Q2 2022 in Review

Parallax Volatility Advisers sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 175 shares — an estimated $217K sold.

Parallax Volatility Advisers first reported a position in QNCX in Q1 2022 and held it in 1 quarter. The position peaked at $217K in Q1 2022. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Parallax Volatility Advisers reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 175 Quince Therapeutics shares in Q2 2022, an estimated $217K.
  • Parallax Volatility Advisers first reported a position in Quince Therapeutics in Q1 2022 and held it in 1 quarter.
  • Parallax Volatility Advisers's Quince Therapeutics position peaked at $217K in Q1 2022.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Parallax Volatility Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.